These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 32019528

  • 1. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
    Wong CKH, Chen J, Fung SKS, Mok M, Cheng YL, Kong I, Lo WK, Lui SL, Chan TM, Lam CLK.
    BMC Nephrol; 2020 Feb 04; 21(1):42. PubMed ID: 32019528
    [Abstract] [Full Text] [Related]

  • 2. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
    Wong CKH, Chen J, Fung SKS, Mok MMY, Cheng YL, Kong I, Lo WK, Lui SL, Chan TM, Lam CLK.
    Nephrol Dial Transplant; 2019 Sep 01; 34(9):1565-1576. PubMed ID: 30668781
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F, Lau T, Luo N.
    Nephrology (Carlton); 2016 Aug 01; 21(8):669-77. PubMed ID: 26566750
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y, Mugford M, Tangcharoensathien V.
    Value Health; 2007 Aug 01; 10(1):61-72. PubMed ID: 17261117
    [Abstract] [Full Text] [Related]

  • 5. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
    Liu J, Hutton DW, Gu Y, Hu Y, Li Y, Ma L, Zeng X, Fu P.
    Perit Dial Int; 2020 Mar 01; 40(2):193-201. PubMed ID: 32063196
    [Abstract] [Full Text] [Related]

  • 6. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
    Bayani DBS, Almirol BJQ, Uy GDC, Taneo MJS, Danguilan RS, Arakama MI, Lamban AB, de Leon D, Pamugas GEP, Luz AC, Teerawatananon Y.
    Nephrology (Carlton); 2021 Feb 01; 26(2):170-177. PubMed ID: 33207027
    [Abstract] [Full Text] [Related]

  • 7. Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease.
    Assanatham M, Pattanaprateep O, Chuasuwan A, Vareesangthip K, Supasyndh O, Lumpaopong A, Susantitaphong P, Limkunakul C, Ponthongmak W, Chaiyakittisopon K, Thakkinstian A, Ingsathit A.
    BMC Health Serv Res; 2022 Nov 21; 22(1):1384. PubMed ID: 36411422
    [Abstract] [Full Text] [Related]

  • 8. The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.
    Liu FX, Treharne C, Culleton B, Crowe L, Arici M.
    BMC Nephrol; 2014 Oct 02; 15():161. PubMed ID: 25278356
    [Abstract] [Full Text] [Related]

  • 9. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
    Surendra NK, Abdul Manaf MR, Hooi LS, Bavanandan S, Mohamad Nor FS, Firdaus Khan SS, Meng OL, Abdul Gafor AH.
    PLoS One; 2019 Oct 02; 14(10):e0218422. PubMed ID: 31644577
    [Abstract] [Full Text] [Related]

  • 10. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?
    Yousefi M, Rezaei S, Hajebrahimi S, Falsafi N, Keshvari-Shad F.
    BMC Nephrol; 2024 Mar 06; 25(1):85. PubMed ID: 38448887
    [Abstract] [Full Text] [Related]

  • 11. Cost-Effectiveness of High Dose Hemodialysis in Comparison to Conventional In-Center Hemodialysis in the Netherlands.
    Beby AT, Cornelis T, Zinck R, Liu FX.
    Adv Ther; 2016 Nov 06; 33(11):2032-2048. PubMed ID: 27664108
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score.
    Chang YT, Hwang JS, Hung SY, Tsai MS, Wu JL, Sung JM, Wang JD.
    Sci Rep; 2016 Jul 27; 6():30266. PubMed ID: 27461186
    [Abstract] [Full Text] [Related]

  • 13. Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.
    Afiatin, Khoe LC, Kristin E, Masytoh LS, Herlinawaty E, Werayingyong P, Nadjib M, Sastroasmoro S, Teerawattananon Y.
    PLoS One; 2017 Jul 27; 12(5):e0177436. PubMed ID: 28545094
    [Abstract] [Full Text] [Related]

  • 14. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F, Devlin N, Luo N.
    Value Health; 2019 Jan 27; 22(1):45-49. PubMed ID: 30661633
    [Abstract] [Full Text] [Related]

  • 15. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.
    Treharne C, Liu FX, Arici M, Crowe L, Farooqui U.
    Appl Health Econ Health Policy; 2014 Aug 27; 12(4):409-20. PubMed ID: 25017433
    [Abstract] [Full Text] [Related]

  • 16. Home Dialysis Is Associated with Lower Costs and Better Survival than Other Modalities: A Population-Based Study in Ontario, Canada.
    Krahn MD, Bremner KE, de Oliveira C, Dixon SN, McFarlane P, Garg AX, Mitsakakis N, Blake PG, Harvey R, Pechlivanoglou P.
    Perit Dial Int; 2019 Aug 27; 39(6):553-561. PubMed ID: 31582466
    [Abstract] [Full Text] [Related]

  • 17. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.
    Yang F, Devlin N, Luo N.
    Eur J Health Econ; 2019 Feb 27; 20(1):99-105. PubMed ID: 29948432
    [Abstract] [Full Text] [Related]

  • 18. Cost-Utility Analysis of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis for Thai Patients With End-Stage Renal Disease.
    Thaweethamcharoen T, Sritippayawan S, Noparatayaporn P, Aiyasanon N.
    Value Health Reg Issues; 2020 May 27; 21():181-187. PubMed ID: 32044691
    [Abstract] [Full Text] [Related]

  • 19. Health economic evaluations: the special case of end-stage renal disease treatment.
    Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS.
    Med Decis Making; 2002 May 27; 22(5):417-30. PubMed ID: 12365484
    [Abstract] [Full Text] [Related]

  • 20. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF, Dratwa M, Wiedemann ME.
    Nephrol Dial Transplant; 1999 May 27; 14 Suppl 6():31-41. PubMed ID: 10528710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.